Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAston Martin Lagonda Regulatory News (AML)

Share Price Information for Aston Martin Lagonda (AML)

Share Price is delayed by 15 minutes
Get Live Data
41.12    -1.44 (-3.38%)
Bid:
41.06
Ask:
43.48
Spread: 2.42 (5.894%)
Market Cap: £416.42m
AML Live PriceLast checked at - London Stock Exchange

Intraday Aston Martin Lagonda Share Chart

Form 8.3 - Aston Martin Lagonda

26 Jul 2019 10:31

RNS Number : 8772G
Baillie Gifford & Co.
26 July 2019
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Baillie Gifford & Co

(b) Owner or controller of interests and short

positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose

relevant securities this form relates:

Use a separate form for each offeror/offeree

Aston Martin Lagonda Global Holdings Plc

(d) If an exempt fund manager connected with an

offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

25 July 2019

(f) In addition to the company in 1(c) above, is the

discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

0.01p Ordinary

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned

and/or controlled:

15,432,846

6.77

 

 

(2) Cash-settled derivatives:

 

 

 

 

(3) Stock-settled derivatives

(including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

15,432,846

6.77

 

 

 

All interests and all short positions should be disclosed.

 

Details  of  any  open  stock-settled  derivative  positions  (including  traded  options),  or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to

which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3.  DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)  Purchases and sales

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

0.01p Ordinary

Sale

2,951

7.0162

 

(b) Cash-settled derivative transactions

 

Class of

relevant security

Product

description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of

reference securities

Price per

unit

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class

of relevant security

Product

description e.g. call option

Writing,

purchasing, selling, varying etc.

Number

of securities to which option relates

Exercise

price per unit

Type

e.g. American, European etc.

Expiry

date

Option

money paid/ received per unit

 

 

 

 

 

 

 

 

 

(ii) Exercise

 

Class of

relevant security

Product

description

e.g. call option

Exercising/

exercised against

Number of

securities

Exercise price

per unit

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached? NO

 

 

 

Date of disclosure:

26.07.2019

Contact name:

Alan Gilliland-Patterson

Telephone number:

0131 275 3779

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information

Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at  www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETUNUKRKWABURR
Date   Source Headline
4th Jun 20267:00 amRNSIssue of equity to satisfy share awards
15th May 20267:00 amRNSIssue of equity to satisfy employee share awards
6th May 202612:51 pmRNSVoting results of AGM 2026
29th Apr 20267:00 amRNSQ1 results for three months ended 31 March 2026
25th Mar 20269:53 amRNSAnnual Financial Report
9th Mar 202612:12 pmRNSResult of Meeting
25th Feb 20267:00 amRNSPreliminary Results FY2025
20th Feb 20267:00 amRNSNotice of GM and FY 2025 Trading Update
29th Oct 20257:00 amRNSQ3 results for the quarter ended 30 September 2025
6th Oct 20257:00 amRNSQ3 2025 Trading Update and revised outlook
10th Sep 202511:33 amRNSDirector/PDMR Shareholding
5th Sep 20257:00 amRNSIssue of equity to satisfy employee share awards
30th Jul 20257:00 amRNSInterim results
28th Jul 20254:33 pmRNSDirectorate Change
27th May 202510:13 amRNSDirector/PDMR Shareholding
27th May 202510:12 amRNSDirector/PDMR Shareholding
15th May 202510:38 amRNSHolding(s) in Company
13th May 20255:26 pmRNSHolding(s) in Company
13th May 202510:33 amRNSDirector/PDMR Shareholding
13th May 202510:31 amRNSDirector/PDMR Shareholding
13th May 202510:26 amRNSDirector/PDMR Shareholding
12th May 20255:53 pmRNSHolding(s) in Company
12th May 20251:13 pmRNSHolding(s) in Company
12th May 202512:52 pmRNSHolding(s) in Company
7th May 20252:45 pmRNSDirector/PDMR Shareholding
7th May 20251:15 pmRNSResult of General Meeting and issue of equity
7th May 20251:07 pmRNSVoting Result of AGM
30th Apr 20257:00 amRNS1st Quarter Results
17th Apr 20258:57 amRNSNotice of General Meeting
16th Apr 20253:20 pmRNSDirector Declaration
31st Mar 20255:11 pmRNSStatement regarding media comments
31st Mar 20257:00 amRNSProposed investment by Yew Tree Consortium
26th Mar 20259:24 amRNSAnnual Financial Report
26th Feb 20257:00 amRNSPreliminary results year ended 31 December 2024
25th Feb 202510:00 amRNSIndependent Non-executive Director appointment
7th Feb 20255:29 pmRNSHolding(s) in Company
13th Dec 20249:00 amRNSDirectorate Change
4th Dec 20244:00 pmRNSHolding(s) in Company
29th Nov 20244:15 pmRNSHolding(s) in Company
29th Nov 20241:01 pmRNSHolding(s) in Company
29th Nov 202412:46 pmRNSDirector/PDMR Shareholding Replacement
29th Nov 202412:18 pmRNSDirector/PDMR Shareholding
29th Nov 202412:17 pmRNSDirector/PDMR Shareholding
29th Nov 202412:11 pmRNSDirector/PDMR Shareholding
27th Nov 20247:00 amRNSResult of Equity Issue
26th Nov 20245:06 pmRNSIssue of Equity
26th Nov 20244:58 pmRNSIssue of Equity
6th Nov 202410:37 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNS3rd Quarter Results
30th Sep 20247:00 amRNSTrading Update and adjustment to FY 2024 guidance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.